A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer

NCT04031885 · clinicaltrials.gov ↗
PHASE4
Phase
TERMINATED
Status
4
Enrollment
INDUSTRY
Sponsor class

Stopped Business decision based on the inability to enroll subjects into the trial

Conditions

Interventions

Sponsor

Eli Lilly and Company